Notes
The study was funded by Amgen (Europe) GmbH, Switzerland.
Reference
Villa G, et al. Cost-Effectiveness of Evolocumab in Patients With High Cardiovascular Risk in Spain. Clinical Therapeutics : 31 Mar 2017. Available from: URL: http://doi.org/10.1016/j.clinthera.2017.02.011
Rights and permissions
About this article
Cite this article
Evolocumab good option for high CV-risk patients in Spain. PharmacoEcon Outcomes News 776, 18 (2017). https://doi.org/10.1007/s40274-017-3920-0
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-017-3920-0